A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.

The present disclosure relates to an oriental medicine composition effective for thyroid hormone level normalization, and more particularly, to an oriental medicine composition for treating thyroid diseases, such as hypothyroidism or hyperthyroidism.

The present disclosure relates to an oriental medicine composition effective for thyroid hormone level normalization, and more particularly, to an oriental medicine composition for treating thyroid diseases, such as hypothyroidism or hyperthyroidism.

The present disclosure relates to an oriental medicine composition effective for thyroid hormone level normalization, and more particularly, to an oriental medicine composition for treating thyroid diseases, such as hypothyroidism or hyperthyroidism.

Disclosed herein are formulations of a poly-herbal synergistic composition which exhibit marked immunomodulatory, anticancer, antiviral and anti-inflammatory properties. Also disclosed are the methods of preparing and using the same.

Disclosed herein are formulations of a poly-herbal synergistic composition which exhibit marked immunomodulatory, anticancer, antiviral and anti-inflammatory properties. Also disclosed are the methods of preparing and using the same.

Disclosed herein are formulations of a poly-herbal synergistic composition which exhibit marked immunomodulatory, anticancer, antiviral and anti-inflammatory properties. Also disclosed are the methods of preparing and using the same.

An object of the present invention is to provide a senescence retarding agent that delays the onset of senescence symptoms and extends longevity, and is superior in safety. The senescence retarding agent of the present invention that achieves the object is characterized by containing a plant fermentation product as an active ingredient, the plant fermentation product being a mixture of the following: (a) a koji mold-fermented product of one or more kinds of beans and/or cereals selected from the group consisting of barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese millet, foxtail millet, and millet; (b) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of fruits selected from the group consisting of mikan (mandarin orange), grape, apple, yama-budo (crimson glory grape), peach, kaki (Japanese persimmon), papaya, nashi (Japanese pear), watermelon, ume (Japanese apricot), fig, karin (Chinese quince), pumpkin, kumquat, yuzu (Chinese lemon), loquat, apricot, jujube, chestnut, matatabi (silvervine), and sumomo (Japanese plum); (c) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of root crops and/or potatoes selected from the group consisting of murasaki-imo (purple sweet potato), kikuimo (Jerusalem artichoke), carrot, onion, satsuma-imo (sweet potato), satoimo (taro), jinenzyo (Japanese yam), daikon (Japanese radish), akakabu (red turnip), gobo (burdock root), renkon (lotus root), yacon, yuri-ne (lily bulb), kuwai (arrowhead), ginger, garlic, and turmeric; (d) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of flowers and/or leaf vegetables selected from the group consisting of cabbage, shiso (perilla), mulberry leaves, dokudami (Korean houttuynia), yomogi (wormwood), kumazasa (kuma bamboo grass), and dandelion; (e) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seaweeds selected from the group consisting of kombu (sea tangle), wakame (Undaria pinnatifida), and mozuku (Nemacystus decipiens); (f) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seeds selected from the group consisting of black sesame seeds, walnuts, and ginkgo nuts; and (g) a yeast- and/or lactic acid bacterium-fermented product of one or two kinds of mushrooms selected from the group consisting of maitake (Grifola frondosa) and shiitake (Lentinus edodes).

An object of the present invention is to provide a senescence retarding agent that delays the onset of senescence symptoms and extends longevity, and is superior in safety. The senescence retarding agent of the present invention that achieves the object is characterized by containing a plant fermentation product as an active ingredient, the plant fermentation product being a mixture of the following: (a) a koji mold-fermented product of one or more kinds of beans and/or cereals selected from the group consisting of barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese millet, foxtail millet, and millet; (b) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of fruits selected from the group consisting of mikan (mandarin orange), grape, apple, yama-budo (crimson glory grape), peach, kaki (Japanese persimmon), papaya, nashi (Japanese pear), watermelon, ume (Japanese apricot), fig, karin (Chinese quince), pumpkin, kumquat, yuzu (Chinese lemon), loquat, apricot, jujube, chestnut, matatabi (silvervine), and sumomo (Japanese plum); (c) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of root crops and/or potatoes selected from the group consisting of murasaki-imo (purple sweet potato), kikuimo (Jerusalem artichoke), carrot, onion, satsuma-imo (sweet potato), satoimo (taro), jinenzyo (Japanese yam), daikon (Japanese radish), akakabu (red turnip), gobo (burdock root), renkon (lotus root), yacon, yuri-ne (lily bulb), kuwai (arrowhead), ginger, garlic, and turmeric; (d) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of flowers and/or leaf vegetables selected from the group consisting of cabbage, shiso (perilla), mulberry leaves, dokudami (Korean houttuynia), yomogi (wormwood), kumazasa (kuma bamboo grass), and dandelion; (e) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seaweeds selected from the group consisting of kombu (sea tangle), wakame (Undaria pinnatifida), and mozuku (Nemacystus decipiens); (f) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seeds selected from the group consisting of black sesame seeds, walnuts, and ginkgo nuts; and (g) a yeast- and/or lactic acid bacterium-fermented product of one or two kinds of mushrooms selected from the group consisting of maitake (Grifola frondosa) and shiitake (Lentinus edodes).

The present invention provides a drug combination for the treatment of infertility and its crude drug comprises the medical ingredients with their weight proportions listed as below: 10-20 amounts by weight of Rehmannia, 10-20 amounts by weight of Chinese Peony, 10-20 amounts by weight of Asiatic Dogwood, 10-20 amounts by weight of Chinese Yam, 10-20 amounts by weight of Poria, 15-25 amounts by weight of Astragalus, 15-25 amounts by weight of Codonopsis, 10-20 amounts by weight of Epimedium and 10-20 amounts by weight of Jujube. The compatibility of this drug combination invented is precise, appropriate and possess outstanding curative effects. As shown in many experiments, the drug combination invented is safe and reliable, its toxic & side-effect is low and it has obvious improvement effects on female infertility caused by androgen, fallopian tube inflammation, tubal blockage and other factors. Furthermore, it can not only significantly improve the success rate of pregnancy, but also improve immunity and enhance the body's anti-fatigue and hypoxia tolerance. In short, the invention provides a safe and reliable new choice for clinical medication.